Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HPV-16/18 AS04-adjuvanted vaccine in women aged 26 years and older
2005-002546-20Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant human papillomavirus bivalent (types 16 and 18) vaccine in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by GSK. Primary endpoint: Primary efficacy endpoint. Started Oct 2005; status: completed.
02
Drugs
recombinant human papillomavirus bivalent (types 16 and 18) vaccine
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2005-002546-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002546-20.